Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 309,268 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 309,268 shares of Dyne Therapeutics stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $21.28, for a total value of $6,581,223.04. Following the transaction, the director directly owned 1,016,633 shares in the company, valued at approximately $21,633,950.24. The trade was a 23.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Trading Up 4.5%

Dyne Therapeutics stock opened at $22.21 on Wednesday. The firm has a 50 day moving average of $18.52 and a 200 day moving average of $18.12. The firm has a market capitalization of $3.67 billion, a price-to-earnings ratio of -6.90 and a beta of 1.09. Dyne Therapeutics, Inc. has a 12-month low of $8.06 and a 12-month high of $25.00. The company has a current ratio of 19.92, a quick ratio of 19.92 and a debt-to-equity ratio of 0.17.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Monday, May 11th. The company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.04. During the same quarter in the prior year, the firm posted ($1.05) EPS. As a group, research analysts predict that Dyne Therapeutics, Inc. will post -3 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC purchased a new position in shares of Dyne Therapeutics during the first quarter valued at about $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Dyne Therapeutics by 5.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock valued at $597,000 after buying an additional 2,886 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in Dyne Therapeutics by 58.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock valued at $10,407,000 after buying an additional 366,183 shares in the last quarter. Caxton Associates LLP purchased a new position in Dyne Therapeutics during the 1st quarter valued at approximately $157,000. Finally, Creative Planning grew its holdings in Dyne Therapeutics by 23.8% during the 2nd quarter. Creative Planning now owns 14,541 shares of the company’s stock valued at $138,000 after buying an additional 2,797 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on DYN shares. Chardan Capital restated a “buy” rating and set a $38.00 target price on shares of Dyne Therapeutics in a research note on Monday, March 9th. TD Cowen started coverage on Dyne Therapeutics in a research note on Friday. They issued a “buy” rating for the company. Wall Street Zen raised Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 20th. Jefferies Financial Group restated a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, March 9th. Finally, Evercore set a $33.00 price objective on Dyne Therapeutics in a research note on Friday, May 15th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $34.17.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.